Analytical Data
-
Gene name
TCL1B
- Application
-
Alternative Names
TCL1B；TCL1；T-cell leukemia/lymphoma Protein 1B
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95988
-
Expression Region
1-128aa
-
AA Sequence
MASEASVRLG VPPGRLWIQR PGIYEDEEGR TWVTVVVRFN PSRREWARAS QGSRYEPSIT VHLWQMAVHT RELLSSGQMP FSQLPAVWQL YPGRKYRAAD SSFWEIADHG QIDSMEQLVL TYQPERKD
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TCL1B, or T-cell leukemia/lymphoma 1B, is a gene located on chromosome 14 that has garnered attention due to its involvement in certain types of cancers, particularly T-cell lymphomas. Research indicates that TCL1B acts as an oncogene, playing a crucial role in cell proliferation and survival. The protein encoded by TCL1B enhances signaling pathways that contribute to the transformation of normal T-cells into malignant ones. Its overexpression is often associated with aggressive forms of T-cell lymphoma, making it a significant biomarker for diagnosis and prognosis. Recent studies have focused on the molecular mechanisms by which TCL1B promotes oncogenesis, including its interaction with various signaling pathways and proteins. Additionally, the exploration of TCL1B as a therapeutic target is of great interest, as inhibiting its function could provide new strategies for treating T-cell malignancies. Understanding the structure and function of the TCL1B recombinant protein is fundamental for developing these potential therapies, as it allows researchers to assess its interactions and effects in a controlled environment. Overall, the research on TCL1B not only enhances our understanding of T-cell lymphoma pathology but also paves the way for innovative treatment approaches in the field of oncology.
